Major adverse cardiovascular events

The reduction in sudden cardiac death with TXL showed a trend toward benefit but did not reach statistical significance. Other cardiovascular events including heart failure, arrhythmias, thrombosis, cerebral ischaemia, and hospital readmissions were reduced by 59% relative risk with TXL. TXL significantly reduced myocardial infarction by 56% relative risk across nine studies, though the absolute effect size was smaller than for other outcomes. TXL significantly reduced the need for repeat revascularisation by 72% relative risk, with an NNT of 15. TXL significantly reduced angina incidence by 68% relative risk across nine studies, with an NNT of 14. MACE incidence rates were 10.38, 25.24, and 75.23 per 1000 person-years for normal, microalbuminuria, and dominant proteinuria groups respectively. MACE incidence increased progressively with higher UACR categories, with the dominant proteinuria group having the highest hazard. During follow-up, 8.49% of participants experienced MACE. Fine-Gray competing risk analysis confirmed the primary Cox model results for MACE after accounting for non-cardiovascular death. Some MACE events occurred without dual biomarker elevation, so biomarker st…